Zhao Shankun, Xu Youwen, Wu Weizhou, Wang Pan, Wang Yichao, Jiang Hao, Zhu Jie
Department of Urology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Department of Clinical Laboratory, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Front Oncol. 2021 Jun 25;11:693295. doi: 10.3389/fonc.2021.693295. eCollection 2021.
Cholangiocarcinoma (CCA), a high mortality malignant carcinoma characterized by advanced disease and frequent recurrence, constitutes a major challenge for treatment and prognosis. AT-rich interaction domain 1A () variation is a distinct genetic entity in CCA, getting mounting concerns recently. Here, we comprehensively reviewed the clinical significance and molecular mechanisms of alterations in CCA. Based on the independent data derived from 29 relevant studies, the variation rate of in intrahepatic and extrahepatic CCA is reported at 6.9-68.2% and 5-55%, respectively. Most of the included studies (28/29, 96.6%) suggest that serves as a tumor suppressor in CCA. variation may be an important prognostic indicator to predict disease mortality, metastasis, and recurrence in patients with CCA. Multifactorial molecular mechanisms are involved in the relationship between variations and the pathogenesis and pathophysiology of CCA, including disruption of the cell cycle, chromatin remodeling, oxidative stress damage, DNA hypermethylation, and the interaction of multiple genes being affected. This review describes that variation might be a potential diagnostic and prognostic biomarker for CCA. Future diagnoses and treatments targeting hint towards a precision medicine strategy in the management of CCA.
胆管癌(CCA)是一种死亡率高的恶性肿瘤,其特点是疾病进展晚期且频繁复发,对治疗和预后构成重大挑战。富含AT的相互作用结构域1A()变异是CCA中一种独特的遗传实体,最近受到越来越多的关注。在此,我们全面综述了CCA中改变的临床意义和分子机制。基于来自29项相关研究的独立数据,肝内和肝外CCA中的变异率分别报告为6.9 - 68.2%和5 - 55%。大多数纳入研究(28/29,96.6%)表明在CCA中作为一种肿瘤抑制因子。变异可能是预测CCA患者疾病死亡率、转移和复发的重要预后指标。多因素分子机制参与了变异与CCA发病机制和病理生理学之间的关系,包括细胞周期破坏、染色质重塑、氧化应激损伤、DNA高甲基化以及多个受影响基因的相互作用。本综述表明变异可能是CCA的一种潜在诊断和预后生物标志物。未来针对的诊断和治疗暗示了CCA管理中的精准医学策略。